Documents in the NTIS Technical Reports collection are the results of federally funded research. They are directly submitted to or collected by NTIS from Federal agencies for permanent accessibility to industry, academia and the public.  Before purchasing from NTIS, you may want to check for free access from (1) the issuing organization's website; (2) the U.S. Government Printing Office's Federal Digital System website http://www.gpo.gov/fdsys; (3) the federal government Internet portal USA.gov; or (4) a web search conducted using a commercial search engine such as http://www.google.com.
Accession Number PB2013-108843
Title Emergency Department Visits Involving Buprenorphine.
Publication Date Jan 2013
Media Count 7p
Personal Author N/A
Abstract Buprenorphine is a medication used to treat opioid addiction. A properly prescribed dose of buprenorphine can help opioid-addicted individuals to stop misusing opioids without experiencing withdrawal symptoms. Although buprenorphine is itself an opioid, and can thus have the same effects as other opioids (e.g., heroin, oxycodone), its maximum effects are less than those of other opioids. Therefore, with buprenorphine there is a decreased risk of abuse, addiction, and side effects compared with other opioids. Buprenorphine was approved for use in the United States for the treatment of opioid dependence in 2002 and is primarily available in two formulations: one that contains only buprenorphine (Subutex) and one that contains buprenorphine and naloxone (Suboxone). Naloxone reverses opioid overdoses and prevents buprenorphine from being misused by injection. Most of the buprenorphine used for treatment in the United States is the buprenorphine-naloxone formulation, which can be prescribed by certified physicians. In this report, buprenorphine refers to both formulations of the drug. Availability of buprenorphine is less restricted than other treatments for opioid dependence, such as methadone, which can only be administered in specialized clinics. Although this availability can increase access to treatment, it can also increase the potential for diversion and misuse by those who are not opioid dependent. Such use can lead to buprenorphine dependence or abuse.
Keywords Buprenorphine
Doses
Drug addiction
Drug treatment programs
Drugs
Emergency visits
Heroine
Medical services
Methadone
Opioid treatment
Oxycodone
Side effects
Withdrawal

 
Source Agency Substance Abuse and Mental Health Services Administration
NTIS Subject Category 57E - Clinical Medicine
57Q - Pharmacology & Pharmacological Chemistry
57U - Public Health & Industrial Medicine
92C - Social Concerns
Corporate Author Substance Abuse and Mental Health Services Administration, Rockville, MD.
Document Type Technical report
Title Note N/A
NTIS Issue Number 1319
Contract Number N/A

Science and Technology Highlights

See a sampling of the latest scientific, technical and engineering information from NTIS in the NTIS Technical Reports Newsletter

Acrobat Reader Mobile    Acrobat Reader